%PDF-1.4
%
44 0 obj
<>
endobj
41 0 obj
<>
endobj
114 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2003-09-08T16:29:50Z
2024-03-28T02:56:44-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T02:56:44-07:00
application/pdf
Heather
2002-163.oct
uuid:d48c240d-1dd1-11b2-0a00-8708271d5700
uuid:d48c240f-1dd1-11b2-0a00-bf0000000000
endstream
endobj
30 0 obj
<>
endobj
31 0 obj
<>
endobj
45 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 18 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 20 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 22 0 R/Type/Page>>
endobj
12 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 24 0 R/Type/Page>>
endobj
131 0 obj
[136 0 R]
endobj
132 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 74.4 714.5293 Tm
(etanercept and methotrexate in patients with early rheumatoid)Tj
0 -1.25 TD
(arthritis. N Engl J Med 2000;343:1586-93.)Tj
-2.175 -1.25 Td
[(12.)-875 (Genovese MC, Bathon JM, Martin R)55 (W)92 (, et al. Etanercept versus)]TJ
2.175 -1.25 Td
[(methotrexate in patients with early rheumatoid arthritis: )18 (T)70 (wo-year)]TJ
T*
[(radiographic and clinical outcomes. )55 (Arthritis Rheum )]TJ
0 Tc 0 Tw T*
(2002;46:1443-50.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(13.)-875 (Hasler F)80 (, van de Putte L, Dumont E, et al. Safety and ef)18 (ficacy of)]TJ
2.175 -1.25 Td
(TNF neutralization by lenercept in patients with rheumatoid)Tj
T*
[(arthritis exposed to a single dose [abstract]. )55 (Arthritis Rheum)]TJ
0 Tc T*
(1996;39 Suppl:S243.)Tj
-0.00011 Tc 30.825 11.25 Td
[(14.)-875 (Furst D, )18 (W)80 (eisman M, Paulus H, et al. Neutralization of )18 (TNF by)]TJ
2.175 -1.25 Td
[(lenercept \(TNFR 55 )18 (TgGt, Ro 45-2081\) in patients with rheumatoid)]TJ
T*
(arthritis treated for 3 months: Results of a phase II trial [abstract].)Tj
T*
(Arthritis Rheum 1996;39 Suppl:S243.)Tj
-2.175 -1.25 Td
[(15.)-875 (Rau R, Sander O, van Riel P)111 (, et al. Intravenous human recombinant)]TJ
2.175 -1.25 Td
(TNF receptor p55-Fc IgG1 fusion protein, Ro 45-2081: Double-)Tj
T*
(blind, placebo-controlled dose finding study in long-standing,)Tj
T*
(active rheumatoid arthritis. J Rheumatol 2003;30:680-90. )Tj
ET
0 0 0 0 k
420 777 137 -27 re
f*
0 0 0 1 K
54 54 m
558 54 l
S
BT
0 0 0 1 k
/T1_1 1 Tf
8 0 0 8 420.3613 35.9844 Tm
(The Journal of Rheumatology 2003; 30:10)Tj
0 Tc 0 Tw -45.7952 -0.0313 Td
(2126)Tj
ET
0 0 0 0 k
/GS0 gs
109.25 59.1 396.47 -10.84 re
f*
0.5 w
109.25 59.1 396.47 -10.84 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
ET
/GS2 gs
BT
/T1_2 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2003. All rights reserved.)Tj
ET
Q
BT
0 g
/GS3 gs
/T1_3 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS3 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS3 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
24 0 obj
<>stream
8;Z\t#nDSA$j?>)+7sb\6>T=MWbBj\68K_uM.D#dR,&37Bi!2;/Uaf+j&h&A>]%JY
^TC;2c+^=Ye`qm8N+n?Q8Zt2RPoCp&gOrHqJ#FmY@%2m`,bgWlW
4&a;rV#eU\:HH3kM\]GH9-s%h/C+%d#\L=fRAUOqW6hZTCOV3hAh`6mi==&6rU;a)
h)><6zzIn&$-,4\3C<-?f9X-M*K^Wl)q49bd*Y>h:~>
endstream
endobj
28 0 obj
[/Indexed/DeviceRGB 255 27 0 R]
endobj
27 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
55 0 obj
<>
endobj
51 0 obj
<>
endobj
73 0 obj
<>
endobj
120 0 obj
<>
endobj
47 0 obj
<>
endobj
66 0 obj
<>stream
HU{PSg7Ë!ܥjU
jh0KG(!G!! "JxYT@RVK:.3usӏns;3q|ᡡ+#"tNYB0u|18xb;e;}D?j~^mߢ.qfOO#q[v_Vq\"LI+~K~okzDO. DRzgzX!$ɾ49-~S+%@mJZ&IH$Gh!:L.3tBzYRa0A"H}c`\9q0wakIl#mby0#cJl7_ :'"#v".Ec?nZWwOݼyGtrh[lA{U98Hni]Fi{BLޫBˑ=zG/*Tz.ܾ;020=S?fѰ#.Wė_ z
eL6VfGeKY,{TVv1\{H!'AS!rDK9`ɾ(YovV'`7~qËnou*])3Y
ud6zdl[Nsy&o
`ܭk(m3# 8j &DW-F*H=!S&Nb|yxWs "y2Ć@XZ
ݺ.̸+xDRQbUj56E#?B& ?O9#Pqg1QͭmgJ[&ʳieXtZ*YHZPQx/HKIT{pTQ&SU):=\=vEy&f6_<ɥElN7f6p}H09 2O^*C
h;} /MH_6p0E΅Q(
wa)q!D/wPx~V)ت6JSJe4ݐoSh_
!@+a[!ġ%ա-!+igY3~ӄj={o+MO5L/ ;'7>%9,_`O5k)+E+7!{9υqh'HK(vN`.Oib~-:69%
jehswYd&yr^eihGɩokk0p^
֍]"ڿm{횧ywc+Y